Rationalizing and mitigating the risk of live-attenuated dengue vaccines

sponsorship: No specific funding was received. The original work of the authors is supported by the European Union's Horizon Europe research and innovation program under Grant Agreement No. 101137459 (Yellow4FLAVI) and by the Flemish Research Foundation (FWO) Excellence of Science (EOS) program Grant No. 40007527 (VirEOS2). The views and conclusions expressed herein are solely those of the authors and do not necessarily reflect the opinions, advice, or endorsements of the funding bodies or their agencies. (European Union's Horizon Europe research and innovation program|101137459, Flemish Research Foundation (FWO) Excellence of Science (EOS) program|40007527)